Metformin Drug Asset Due Diligence Report 2026

This Metformin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

346

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Metformin can convert its Small molecule drug profile and GPD1 x PRKAB1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Metformin (query alias: metformin)
Modality / target	Small molecule drug; GPD1 x PRKAB1; GPD1 modulators, PRKAB1 activators
Highest global status	Phase 2
Originator	Elcelyx Therapeutics, Inc.
Active developers	Peking Union Medical College Hospital, Baylor College of Medicine, University of California, Irvine

The MCP disease footprint includes Mucinous Neoplasm, Pseudomyxoma Peritonei, Ependymoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07226453	Phase 2	Recruiting	30	Proportion of participants with changes in biomarkers between the pre-and post-metformin treated samples (Target Validation Phase)
NCT07693452	Phase 2	Recruiting	15	Proportion of Participants who have completed at least (≥) 80% of planned metformin doses by 6 months
NCT07007221	Phase 2	Withdrawn	Not disclosed	MADRS Score

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Phase 2; n=60; evaluation: not stated. Reported fields: (M-)Protein Concentrations Change(Median) = 7.7 percent change (Full Range, -15.4 to 29.7); -; (M-)Protein Concentrations Change(Median) = -3.2 percent change (Full Range, -33.0 to 20.4)

A Phase II Study of Metformin, Doxycycline, or a Combination of Both Agents in Head and Neck Squamous Cell Carcinoma

Phase 2; n=7; evaluation: not stated. Reported fields: Change in Percentage of CFS Expressing Caveolin-1 at an Intensity of 1+ or Greater Assessed in Tumor-associated Stroma Cells by Immunohistochemistry(Mean) = 32.5 percentage of cells (Full Range, 20 - 70); Change in Percentage of CFS Expressing Caveolin-1 at an Intensity of 1+ or Greater Assessed in Tumor-associated Stroma Cells by Immunohistochemistry(Mean) = 32.5 percentage of cells (Full Range, 20 - 80); -

Randomized Phase II Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Phase 2; n=41; evaluation: not stated. Reported fields: AGE Level Reduction(Median) = 0.49 ng/ml (30% Confidence Interval, -3.32 to 1.18); AGE Level Reduction(Median) = 1.49 ng/ml (30% Confidence Interval, -1.51 to 4.52); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Metformin addresses Mucinous Neoplasm, Pseudomyxoma Peritonei, Ependymoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-03-21	Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration	Phase 3	Financial terms not disclosed
2021-05-12	NephroDI Therapeutics collaborates with Emory University to develop NDI-5033 as a treatment for Nephrogenic diabetes insipidus.	Preclinical	Financial terms not disclosed
2019-05-29	Anji Pharmaceuticals obtains global development rights for late-stage clinical asset, Metformin DR, from Elcelyx Therapeutics to treat type II diabetes with Chronic Kidney Disease.	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for detecting nitrosamine impurity in metformin vildagliptin preparation and application thereof”. The milestone feed surfaced a patent-application signal described as “Tetrahedral framework nucleic acid-metformin compound as well as preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Zero crossing third derivative UV spectrophotometric method for the simultaneous estimation of vildagliptin & metformin in a combined tablet dosage form”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO